JTE-907

JTE-907
(IUPAC) ime
	N-(benzo[1,3]dioksol-5-ilmetil)-7-metoksi-2-okso-8-pentiloksi-1,2-dihidrohinolin-3-karboksamid
Klinički podaci
Identifikatori
CAS broj	282089-49-0
ATC kod	nije dodeljen
PubChem	9867770
Hemijski podaci
Formula	C24H26N2O6
Mol. masa	438,472
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C24H26N2O6/c1-3-4-5-10-30-22-19(29-2)9-7-16-12-17(24(28)26-21(16)22)23(27)25-13-15-6-8-18-20(11-15)32-14-31-18/h6-9,11-12H,3-5,10,13-14H2,1-2H3,(H,25,27)(H,26,28) ; Key: GRAJFFFXJYFVOC-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Verzija za štampanje više nije podržana i može davati greške. Podnovite oznake i koristite ugrađenu mogućnost štampanja preglednika.

JTE-907 je lek koji se koristi u naučnim istraživanjima. On deluje kao selektivni inverzni agonist CB₂ receptora.^[3]^[4] On ima antiinflamatorno dejstvo u životinjskim studijama.^[5] Smatra se da posreduje interakciju između CB₂ receptora u IgE.^[6]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (2001). „In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor”. The Journal of Pharmacology and Experimental Therapeutics 296 (2): 420–5. PMID 11160626.
↑ Raitio KH, Savinainen JR, Vepsäläinen J, Laitinen JT, Poso A, Järvinen T, Nevalainen T (2006). „Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists”. Journal of Medical Chemistry 49 (6): 2022–7. DOI:10.1021/jm050879z. PMID 16539390.
↑ Ueda Y, Miyagawa N, Matsui T, Kaya T, Iwamura H (2005). „Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice”. European Journal of Pharmacology 520 (1–3): 164–71. DOI:10.1016/j.ejphar.2005.08.013. PMID 16153638.
↑ Ueda Y, Miyagawa N, Wakitani K (2007). „Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice”. Life Sciences 80 (5): 414–9. DOI:10.1016/j.lfs.2006.09.026. PMID 17055000.

Povezano

JTE 7-31

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (2001). „In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor”. The Journal of Pharmacology and Experimental Therapeutics 296 (2): 420–5. PMID 11160626.

[4] Raitio KH, Savinainen JR, Vepsäläinen J, Laitinen JT, Poso A, Järvinen T, Nevalainen T (2006). „Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists”. Journal of Medical Chemistry 49 (6): 2022–7. DOI:10.1021/jm050879z. PMID 16539390.

[5] Ueda Y, Miyagawa N, Matsui T, Kaya T, Iwamura H (2005). „Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice”. European Journal of Pharmacology 520 (1–3): 164–71. DOI:10.1016/j.ejphar.2005.08.013. PMID 16153638.

[6] Ueda Y, Miyagawa N, Wakitani K (2007). „Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice”. Life Sciences 80 (5): 414–9. DOI:10.1016/j.lfs.2006.09.026. PMID 17055000.

[1]

[2]

[3]

[4]

[5]

[6]